United Health Products (UEEC) 10-Q 15 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 12, 2022
Cover [Abstract]
Entity Registrant Name	UNITED HEALTH PRODUCTS, INC.
Entity Central Index Key	0001096938
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		229,877,509
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-27781
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	84-1517723
Entity Interactive Data Current	Yes
Entity Address Address Line 1	526 Commerce Circle
Entity Address City Or Town	Mesquite
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89027
City Area Code	877
Local Phone Number	358-3444
Entity Address Address Line 2	Ste. #102

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current Assets
Cash and Cash Equivalents	$ 6,416	$ 21,799
Prepaid and other current assets	14,206	5,000
Total current assets	20,622	26,799
Patents, net	38,475	0
TOTAL ASSETS	59,097	26,799
Current Liabilities
Accounts payable and accrued expenses	1,264,134	826,486
Accrued liabilities - related parties	22,651	3,207
Accrued litigation settlement	400,000	120,000
Promissory note payable	63,739	0
Loans payable - related parties	602,275	219,000
Total current liabilities	2,352,799	1,168,693
TOTAL LIABILITIES	2,352,799	1,168,693
Commitments and Contingencies	0	0
Stockholders' Equity (Deficit)
Series A Convertible Preferred Stock - $0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding	0	0
Common Stock - $0.001 par value, 300,000,000 shares Authorized, 229,877,509 and 228,667,229 shares issued at June 30, 2022 and December 31, 2021	229,877	228,667
Additional Paid-In Capital	71,708,164	71,017,881
Accumulated Deficit	(74,231,743)	(72,388,442)
Total Stockholders' Equity (Deficit)	(2,293,702)	(1,141,894)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 59,097	$ 26,799

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	229,877,509	228,667,229
Common stock, shares outstanding	229,877,509	228,667,229
Series A Convertible Preferred Stock [Member]
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Condensed Statements of Operations (Unaudited)
Revenues	$ 0	$ 0	$ 0	$ 59
Cost of goods sold	0	0	0	25
Gross profit	0	0	0	34
Operating Costs and Expenses
Selling, general and administrative expenses	607,186	1,231,179	1,509,332	27,878,223
Research and development	147,611	68,884	199,966	127,065
Total Operating Expenses	754,797	1,300,063	1,709,298	28,005,288
Loss from Operations	(754,797)	(1,300,063)	(1,709,298)	(28,005,254)
Other Income (Expenses)
Interest expense	(205)	(4,413)	(285)	(225,639)
Interest expense - related party	(11,535)	0	(20,343)	(389,804)
Loss on settlement of debt	(112,500)	0	(113,375)	(35,190)
Other income	0	0	0	304,273
Total other income (expenses)	(124,240)	(4,413)	(134,003)	(346,360)
Net Loss	$ (879,037)	$ (1,304,476)	$ (1,843,301)	$ (28,351,614)
Net Loss per common share:
Basic and diluted	$ 0	$ (0.01)	$ (0.01)	$ (0.13)
Weighted average number of shares outstanding	229,737,399	226,222,528	229,257,932	224,152,495

Condensed Statement of Stockhol

Condensed Statement of Stockholders Equity (Unaudited) - USD ($)	Total	Accumulated Deficit	Common Stock [Member]	Additional Paid-In Capital
Balance, shares at Dec. 31, 2020			189,357,090
Balance, amount at Dec. 31, 2020	$ (953,262)	$ (41,839,259)	$ 189,357	$ 40,696,640
Beneficial conversion feature	234,912	0	$ 0	234,912
Issuance of common stock for services, shares			100,000
Issuance of common stock for services, amount	111,000	0	$ 100	110,900
Sale of common stock, shares			125,000
Sale of common stock, amount	100,000	0	$ 125	99,875
Common stock issued to settle accrued liabilities - related party, shares			152,835
Common stock issued to settle related party advances, shares			25,000
Cancellation of common stock, shares			(117,647)
Common stock issued to settle related party advances, amount	26,750	0	$ 25	26,725
Common stock issued for conversion of convertible notes payable and accrued interest, amount	560,071	0	$ 1,047	559,024
Common stock issued for conversion of convertible notes payable and accrued interest, shares			1,047,139
Stock-based compensation, shares			33,930,000
Common stock issued to settle accrued liabilities - related party, amount	161,964	0	$ 153	161,811
Common stock issued for conversion of convertible notes payable and accrued interest - related party, shares			1,353,111
Cancellation of common stock, amount	0	0	$ (117)	117
Common stock issued for conversion of convertible notes payable and accrued interest - related party, amount	676,555	0	1,353	675,202
Stock-based compensation, amount	26,170,421	0	33,930	26,136,491
Net Loss	(27,047,138)	(27,047,138)	$ 0	0
Balance, shares at Mar. 31, 2021			225,972,528
Balance, amount at Mar. 31, 2021	41,273	(68,886,397)	$ 225,973	68,701,697
Balance, shares at Dec. 31, 2020			189,357,090
Balance, amount at Dec. 31, 2020	(953,262)	(41,839,259)	$ 189,357	40,696,640
Net Loss	(28,351,614)
Balance, shares at Jun. 30, 2021			226,335,524
Balance, amount at Jun. 30, 2021	(1,002,057)	(70,190,873)	$ 226,335	68,962,481
Balance, shares at Mar. 31, 2021			225,972,528
Balance, amount at Mar. 31, 2021	41,273	(68,886,397)	$ 225,973	68,701,697
Common stock issued for conversion of convertible notes payable and accrued interest, amount	30,396	0	$ 37	30,359
Common stock issued for conversion of convertible notes payable and accrued interest, shares			37,996
Stock-based compensation, shares			325,000
Stock-based compensation, amount	230,750	0	$ 325	230,425
Net Loss	(1,304,476)	(1,304,476)	$ 0	0
Balance, shares at Jun. 30, 2021			226,335,524
Balance, amount at Jun. 30, 2021	(1,002,057)	(70,190,873)	$ 226,335	68,962,481
Balance, shares at Dec. 31, 2021			228,667,229
Balance, amount at Dec. 31, 2021	(1,141,894)	(72,388,442)	$ 228,667	71,017,881
Issuance of common stock for services, shares			20,000
Issuance of common stock for services, amount	10,200		$ 20	10,180
Sale of common stock, shares			184,028
Sale of common stock, amount	77,292		$ 184	77,108
Net Loss	(964,264)	(964,264)
Common stock issued to settle accounts payable and accrued liabilities, shares			6,252
Common stock issued to settle accounts payable and accrued liabilities, amount	4,001		$ 6	3,995
Balance, shares at Mar. 31, 2022			228,877,509
Balance, amount at Mar. 31, 2022	(2,014,665)	(73,352,706)	$ 228,877	71,109,164
Balance, shares at Dec. 31, 2021			228,667,229
Balance, amount at Dec. 31, 2021	(1,141,894)	(72,388,442)	$ 228,667	71,017,881
Net Loss	(1,843,301)
Balance, shares at Jun. 30, 2022			229,877,509
Balance, amount at Jun. 30, 2022	(2,293,702)	(74,231,743)	$ 229,877	71,708,164
Balance, shares at Mar. 31, 2022			228,877,509
Balance, amount at Mar. 31, 2022	(2,014,665)	(73,352,706)	$ 228,877	71,109,164
Issuance of common stock for services, shares			200,000
Issuance of common stock for services, amount	96,000		$ 200	95,800
Cancellation of common stock, shares			(250,000)
Cancellation of common stock, amount			$ (250)	250
Net Loss	(879,037)	(879,037)
Common stock issued to settle accounts payable and accrued liabilities, shares			425,000
Common stock issued to settle accounts payable and accrued liabilities, amount	96,000		$ 200	95,800
Issuance of common stock for services - related party, shares			425,000
Issuance of common stock for services - related party, amount	204,000		$ 425	203,575
Common stock issued to settle accounts payable and accrued liabilities, shares			200,000
Common stock issued to settle accounts payable and accrued liabilities - related party, amount	204,000		$ 425	203,575
Balance, shares at Jun. 30, 2022			229,877,509
Balance, amount at Jun. 30, 2022	$ (2,293,702)	$ (74,231,743)	$ 229,877	$ 71,708,164

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows from Operating Activities:
Net (Loss)	$ (1,843,301)	$ (28,351,614)
Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities:
Stock for services and compensation	310,200	26,512,173
Amortization expense	2,025	0
Amortization of debt discount	0	608,710
Loss on settlement of debt	113,375	35,190
Changes in assets and liabilities:
Inventory	0	25
Prepaid and other current assets	(9,206)	(5,000)
Subscription Receivable	0	0
Accounts payable and accrued expenses	500,774	138,167
Accrued liabilities - related party	146,944	236,805
Accrued litigation settlement	380,000	562,000
Net Cash Used In Operating Activities	(399,189)	(263,544)
Cash Flows from Investing Activities:
Purchase of intangible assets	(40,500)	0
Net Cash Used in Investing Activities	(40,500)	0
Cash Flows from Financing Activities:
Proceeds from related party	383,275	20,000
Repayments on loan payable	(36,261)	0
Proceeds from sale of common stock	77,292	100,000
Proceeds from convertible notes payable	0	115,000
Cash flow provided by financing activities	424,306	235,000
Decrease in Cash and Cash Equivalents	15,383	28,544
Cash and Cash Equivalents - Beginning of period	21,799	46,076
CASH AND CASH EQUIVALENTS - END OF PERIOD	6,416	17,532
Supplemental cash flow information:
Cash paid for interest	285	0
Cash paid for income taxes	0	0
Non-cash Investing & Financing Activities:
Cancellation of common stock	250	117
Conversion of convertible notes payable and accrued interest - related party to convertible notes payable and accrued interest	0	176,502
Common stock issued for conversion of convertible notes payable and accrued interest - related party	0	676,555
Common stock issued for conversion of convertible notes payable and accrued interest	0	590,465
Conversion of accounts payable to convertible notes payable	0	90,000
Common stock issued to settle related party advances	0	26,750
Common stock issued to settle accrued liabilities - related party	127,500	161,964
Conversion of accrued liabilities - related party to convertible notes payable - related party	0	112,500
Common stock issued to settle accrued liabilities	63,126	0
Accrued litigation settlement paid with loan payable	100,000	0
Debt discount related to beneficial conversion feature	$ 0	$ 234,912

Organization and Basis of Prepa

Organization and Basis of Preparation	6 Months Ended
	Jun. 30, 2022
Organization and Basis of Preparation
Organization and Basis of Preparation	Note 1. Organization and Basis of Preparation United Health Products, Inc. (the “Company”) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, HemoStyp®, is a neutralized, oxidized, regenerated cellulose (“NORC”) derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. We are in the process of seeking regulatory approval to sell our Hemostyp product line into the U.S. Class III and European Union CE Mark surgical markets. The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on April 1, 2022. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period, have been included.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Significant Accounting Policies
Significant Accounting Policies	Note 2. Significant Accounting Policies Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) as a pandemic. As a result, economic uncertainties have arisen which have the potential to negatively impact the Company’s ability to raise funding and to pursue is business objectives. Other factors that carry financial implications for the Company could occur although the potential impacts are unknown at this time. Cash and Cash Equivalents The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts are currently offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business. Trade Accounts Receivable and Concentration Risk We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers that are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credit issued. There were no provisions for doubtful accounts recorded at June 30, 2022 and December 31, 2021. The Company recorded $0 in bad debt expense for the three and six month periods ended June 30, 2022 and 2021. Stock Based Compensation The Company accounts for share-based compensation under the provisions of ASC 718, Compensation-Stock Compensation The Company accounts for stock compensation arrangements with non-employees in accordance with Accounting Standard Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, Per Share Information Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred net losses for the three and six months ended June 30, 2022 and 2021 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. The total potential common shares as of June 30, 2022 included 30,915,000 of restricted stock units. The total potential common shares as of June 30, 2021 includes 28,325,000 of restricted stock units. Patents Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed. Accumulated amortization as of June 30, 2022 and December 31, 2021 was $2,025 and $0, respectively. Amortization expense for the six months ended June 30, 2022 and 2021 was $2,025 and $0, respectively. Future Amortization Expense Year Amount 2022 (remaining) $ 2,025 2023 4,050 2024 4,050 2025 4,050 2026 4,050 Thereafter 20,250 $ 38,475 Impairment of Long-lived Assets The Company applies the provisions of ASC 360, Property, Plant and Equipment, When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the six months ended June 30, 2022 and 2021, the Company determined no impairment was required. New Accounting Pronouncements The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions
Related Party Transactions	Note 3. Related Party Transactions Loans payable - related parties As of December 31, 2021, Brian Thom, Chief Executive Officer had a loan payable balance of $175,000. During the six months ended June 30, 2022, Mr. Thom loaned the Company $315,000 to pay for operating expenses. As of June 30, 2022, $490,000 is owed to Mr. Thom. The loans have an interest rate of 10% and have a maturity date of December 31, 2022. As of December 31, 2021, Lou Schiliro, the former Chief Operating Officer, had a loan payable balance of $44,000. During the six months ended June 30, 2022, Mr. Schiliro, loaned the Company $64,275 to pay for operating expenses. As of June 30, 2022, $108,275 is owed to Mr. Schiliro. The loans have an interest rate of 10% and have a maturity date of December 31, 2022. During the six months ended June 30, 2022, Kristofer Heaton, Principal Financial Officer, loaned the Company $4,000 to pay for operating expenses. As of June 30, 2022, $4,000 is owed to Mr. Heaton. The loans have an interest rate of 10% and have a maturity date of December 31, 2022. Interest expense – related party on the above loans was $11,535 and $20,343 during the three and six months ended June 30, 2022, respectively. Accrued interest – related party as of June 30, 2022 and December 31, 2021 was $22,651 and $2,308, respectively and has been recorded in accrued liabilities – related party on the balance sheet. Accrued liabilities – related parties As of March 31, 2022 and December 31, 2021, $45,000 and $899 was owed to Mr. Thom for accrued compensation and reimbursable expenses, respectively. During the three months ended June 30, 2022, the Company issued 150,000 shares of common stock to Mr. Thom to settle the accrued compensation and paid him $899 for reimbursable expenses. The common stock had a fair value of $72,000 and the Company recorded $27,000 as a loss on settlement of debt. As of March 31, 2022 and December 31, 2021, $45,000 and $0 was owed to Mr. Schiliro for accrued compensation, respectively. During the three months ended June 30, 2022, the Company issued 150,000 shares of common stock to Mr. Schiliro for the accrued compensation. The common stock had a fair value of $72,000 and the Company recorded $27,000 as a loss on settlement of debt. As of March 31, 2022 and December 31, 2021, $37,500 and $0 was owed to Kristofer Heaton, the Principal Financial Officer, for accrued compensation, respectively. During the three months ended June 30, 2022, the Company issued 125,000 shares of common stock to Mr. Heaton for the accrued compensation. The common stock had a fair value of $60,000 and the Company recorded $22,500 as a loss on settlement of debt. Equity transactions Per the vesting schedules of certain of the Company’s amended RSU Agreements, on January 1, 2021, 6,760,000 shares of common stock were issued to Mr. Douglas Beplate, former Chairman of the Board, 2,000,000 shares of common stock were issued to Mr. Schiliro and 100,000 shares of common stock were issued to Mr. Heaton. On January 6, 2021, the Board of Directors approved the second amendment to the RSU Agreement between the Company and Mr. Beplate in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSUs by issuing 21,970,000 shares of common stock. Further, as a bonus in recognition of Mr. Beplate’s service to the Company and in recruitment of new executive management, the Company issued to Mr. Beplate an additional 2,000,000 shares of common stock. The Company recorded $26,127,300 of stock-based compensation expense during the six months ended June 30, 2021 related to the accelerated vesting of these RSU’s and issuance of common stock. During the six months ended June 30, 2022, the Board of Directors approved an amendment to Mr. Thom’s RSU Agreement dated November 24, 2020. The amendment increased the number of RSU’s granted from 11,500,000 to 13,225,000. The RSU’s are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. During the six months ended June 30, 2022, the Board of Directors approved an RSU Agreement with Robert Denser, Director of the Board. The agreement grants Mr. Denser 1,000,000 RSU’s which are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. During the six months ended June 30, 2022, the Company issued 150,000 shares of common stock each to Mr. Thom and Mr. Schiliro and 125,000 shares of common stock to Mr. Heaton for compensation in lieu of cash. The common stock had a total fair value of $204,000.

Promissory Note Payable

Promissory Note Payable	6 Months Ended
	Jun. 30, 2022
Related Party Transactions
Promissory Note Payable	Note 4. Promissory Note Payable During the six months ended June 30, 2022, the Company reached a settlement agreement related to Patterson’s counterclaim (see Note 6). The Company agreed to pay $120,000 which had previously been accrued as of December 31, 2021. The Company paid $20,000 of the settlement and entered into a $100,000 promissory note with its legal counsel to fund the payment of the remaining balance. The Company paid $36,261 of principal and $285 in interest expense leaving a principal balance of $63,739 and accrued interest of $0 as of June 30, 2022. The note accrues interest at 1% and requires monthly payments of $9,136 until the balance is paid in full. The promissory note is secured by 200,000 shares of restricted common stock which would have demand registration rights and the Company would file a registration statement within 45 days of the request.

Issuances of Securities

Issuances of Securities	6 Months Ended
	Jun. 30, 2022
Issuances of Securities
Issuances of Securities	Note 5. Issuances of Securities Share issuances 2021 During the six months ended June 30, 2021, a total of 32,255,000 shares of common stock were issued to officers, directors and various consultants related to vesting of RSU’s with a total stock-based compensation cost of $24,221,170, 2,000,000 shares of common stock were issued to Mr. Beplate as a stock bonus with a stock-based compensation cost of $2,180,000, 125,000 shares of common stock were sold to an affiliated investor in a private placement for total cash proceeds of $100,000, 100,000 shares of common stock were issued for settlement of a business consulting agreement with a fair value of $111,000, 25,000 shares of commons stock were issued to settle $20,000 of related party advances, 152,835 shares of common stock were issued to settle accrued liabilities – related party worth $133,523, 1,085,135 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest of $590,468, 1,353,111 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest – related party of $676,555 and 117,647 shares of common stock were cancelled reducing common stock by $117 and increasing additional paid-in capital by the same. Share issuances 2022 During the six months ended June 30, 2022, 184,028 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $77,292, 206,252 shares of common stock were issued to various consultants to settle $63,126 of accrued liabilities resulting in a loss on settlement of debt of $36,875, 200,000 shares of common stock with a fair value of $96,000 were issued to consultants for services, 425,000 shares of common stock were issued to settle $127,500 of accrued liabilities – related party (see Note 3) resulting in a loss of settlement of debt of $76,500, 425,000 shares of common stock with a fair value of $204,000 were issued to officers and a former officer of the Company for services (see Note 3), 20,000 shares of common stock with a fair value of $10,200 were issued for legal services and 250,000 shares of common stock were cancelled reducing common stock by $250 and increasing additional paid-in capital by the same. Restricted stock units During the year ended December 31, 2020 the Board of Directors approved amendments to its March 25, 2019 RSU Agreement for certain management and consultants to the Company. The amendment resulted in 9,960,000 of the RSU’s vesting on January 1, 2021. The compensation expense was being amortized on a straight-line basis from the date of the amendment through January 1, 2021 which is the vesting date. Stock-based compensation of $43,121 was recognized as expense during the six months ended June 30, 2021. On January 6, 2021, the Board of Directors approved the second amendment to the Restricted Stock Unit Agreement between the Company and Mr. Beplate, former Chief Executive Officer and former Chairman of the Board, in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSUs by issuing 21,970,000 shares of common stock. As discussed above in Note 3, during the six months ended June 30, 2022, the Board of Directors approved an RSU Agreement in which Robert Denser, Director was granted 1,000,000 RSU’s which are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. In addition, Mr. Thom’s original RSU Agreement was amended. The amendment increased the amount of RSU’s granted from 11,500,000 to 13,225,000. The RSU’s are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. Activity related to our restricted stock units during the six months ended June 30, 2022 was as follows: Weighted Average Grant Number of Date Fair Units Value Total awards outstanding at December 31, 2021 28,190,000 $ 0.96 Units granted 14,225,000 $ 0.43 Units Exercised/Released - $ - Units Cancelled/Forfeited (11,500,000 ) $ 1.18 Total awards outstanding at June 30, 2022 30,915,000 $ 0.63 Management is unable to predict if or when a Covered Transaction or Triggering Event which are vesting milestones under the RSU Agreements governing the restricted stock units will occur and as of June 30, 2022, there was $19,563,950 of unrecognized compensation cost related to unvested restricted stock unit awards.

Accrued Litigation Settlement

Accrued Litigation Settlement	6 Months Ended
	Jun. 30, 2022
Accrued Litigation Settlement
Accrued Litigation Settlement	Note 6. Accrued Litigation Settlement On June 15, 2022, the Security and Exchange Commission’s (SEC) investigation of the Company, initially reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, was settled through the filing of a consent judgment without the Company admitting or denying the SEC’s allegations. As part of the settlement, the Company is required to pay a civil penalty of $450,000, payable in four installments as follows: · $50,000 upon the entry of the judgment; · $100,000 within 90 days of the entry of the judgment; · $150,000 within 180 days of the entry of the judgment; and · $150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days of the entry of the judgment pursuant to U.S.C. Section 1961 The Company made the initial schedule payment of $50,000 towards the civil penalty and as of June 30, 2022 the accrued litigation balance is $400,000.

Litigation

Litigation	6 Months Ended
	Jun. 30, 2022
Accrued Litigation Settlement
Litigation	Note 7. Litigation Philip Forman, who served as Chairman, a director, Chief Executive Officer and Chief Medical Advisor of the Company at various times between 2011 and October 2015, filed a lawsuit against the Company and our then-Chief Executive Officer, Douglas Beplate, in the United States District Court of the District of Nevada. The plaintiff has claimed, among other things: that the June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company, which terminated the Employment Agreement on October 1, 2015, is not enforceable due to lack of consideration; that a July 22, 2015 Stock Purchase Agreement pursuant to which the plaintiff sold Company shares issued to him under the Amendment to a third a party is unenforceable (despite the fact that all payment for the shares under the Stock Purchase Agreement was made); that the plaintiff’s 2014 Employment Agreement remains valid and that he is entitled to cash and stock compensation under that Employment Agreement (without giving regard to the Amendment); and that the Company and Mr. Beplate defrauded the plaintiff relating to the foregoing. The plaintiff is seeking declaratory judgment regarding the parties’ relative rights under the Employment Agreement, the Amendment and the Stock Purchase Agreement; money damages of no less than $2,795,000; and punitive damages of $8,280,000. The Company filed a motion to dismiss the plaintiff’s claims which was denied on March 19, 2020. On May 5, 2021, the plaintiff provided a deposition as instructed by the Court, subsequent to which the Company filed a motion for dismissal of this proceeding . In 2018 an action was commenced in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third-party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading. The third-party plaintiff alleges that the Company and Mr. Beplate refused to have the restrictive legend on the stock certificate removed under Rule 144 and sought compensatory and punitive damages. The Federal court issued an order that the Securities Exchange Commission should review the claim before the District Court renders a final ruling. Discovery appears to be substantially complete and settlement discussions between the third-party plaintiff and the Company have been initiated. On April 22, 2022 the parties entered in a Settlement Agreement wherein the Company would agree to allow the removal of the restrictive legend as permitted under applicable securities laws and distribution of the shares to affiliates of the plaintiffs. Under the Settlement Agreement the Company will make no payments other than to pay expenses related to its own legal counsel. As mentioned in Note 6 above, the Company settled the SEC’s investigation through the filing of a consent judgment on the terms described in the Company’s Form 8-K filed on April 29, 2022, without the Company admitting or denying the SEC’s allegations. Due to uncertainties inherent in litigation, we cannot predict the outcome of the above pending legal proceedings. The Company is or was also a party to the following legal proceedings: On February 7, 2020, the Company filed the Original Petition for Fraud and Breach of Contract in the Texas District Court for the 215th Judicial District of Harris County against defendants Patterson Companies Inc., Patterson Management, L.P., Patterson Veterinary, Inc. and Patterson Logistics Services, Inc., and Animal Health International, Inc. On March 5, 2020, the defendants removed the case to U.S. District Court for Southern District of Texas. The defendants filed their answer in federal court on March 12, 2020. The original August 25, 2020 pretrial deadlines were extended. On January 18, 2022, the Company’s claims were dismissed, with prejudice, by the court. On February 9, 2022, the Company and Patterson reached an agreement on settlement of Patterson’s counterclaim. The Company agreed to pay $120,000 which was accrued as of December 31, 2021. The $120,000 settlement payment was paid in full in February 2022. In August 2020, United Health Products filed suit against its former auditors, Haynie & Company, in Utah State Court, asserting claims related to professional negligence and breach of fiduciary duty. Haynie & Company has denied the allegations. Mediation is scheduled for the last week of August 2022.

Other Income

Other Income	6 Months Ended
	Jun. 30, 2022
Other Income (Expenses)
Other income	Note 8. Other Income The Company received payment of $304,273 from Maxim Group LLC, as full and final settlement of its previously disclosed arbitration between the Company and Maxim that was settled in December 2019. The $304,273 was recorded as other income in the Statement of Operations during the six months ended June 30, 2021.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2022
Subsequent Event
Subsequent Events	Note 9. Subsequent Events The Company has evaluated events from June 30, 2022, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed except as follows: The Company issued a $200,000 convertible note to a non-affiliate bearing interest at 10% with a maturity date of November 30, 2022. The convertible note can be converted into shares of common stock at a conversion price of $0.40 per share. The Company issued a $100,000 convertible note to a non-affiliate with a 7% original issue discount (OID), an interest rate of 10% and maturity date of December 31, 2023. The Company received net proceeds of $93,000 after the OID. The convertible note can be converted into shares of common stock at a conversion price of $0.35 per share. The Company issued a $100,000 convertible note to a Director of the Company with a 7% OID, an interest rate of 10% and maturity date of December 31, 2023. The Company received net proceeds of $93,000 after the OID. The convertible note can be converted into shares of common stock at a conversion price of $0.35 per share. The Board of Directors approved RSU Agreements with four doctors to acquire the patent application and related intellectual property rights in the “Method of Forming and Using a Hemostatic Hydrocolloid”, U.S. Patent Office Serial No. 62/875,798, filed July 18, 2019, in which a total of 16,000,000 RSU’s were granted. The RSU’s are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Significant Accounting Policies
Going Concern	The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) as a pandemic. As a result, economic uncertainties have arisen which have the potential to negatively impact the Company’s ability to raise funding and to pursue is business objectives. Other factors that carry financial implications for the Company could occur although the potential impacts are unknown at this time.
Cash and Cash Equivalents	The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.
Use of Estimates	The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.
Revenue Recognition	The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts are currently offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.
Trade Accounts Receivable and Concentration Risk	We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers that are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credit issued. There were no provisions for doubtful accounts recorded at June 30, 2022 and December 31, 2021. The Company recorded $0 in bad debt expense for the three and six month periods ended June 30, 2022 and 2021.
Stock Based Compensation	The Company accounts for share-based compensation under the provisions of ASC 718, Compensation-Stock Compensation The Company accounts for stock compensation arrangements with non-employees in accordance with Accounting Standard Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,
Per Share Information	Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred net losses for the three and six months ended June 30, 2022 and 2021 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. The total potential common shares as of June 30, 2022 included 30,915,000 of restricted stock units. The total potential common shares as of June 30, 2021 includes 28,325,000 of restricted stock units.
Patents	Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed. Accumulated amortization as of June 30, 2022 and December 31, 2021 was $2,025 and $0, respectively. Amortization expense for the six months ended June 30, 2022 and 2021 was $2,025 and $0, respectively. Future Amortization Expense Year Amount 2022 (remaining) $ 2,025 2023 4,050 2024 4,050 2025 4,050 2026 4,050 Thereafter 20,250 $ 38,475
Impairment of Long-lived Assets	The Company applies the provisions of ASC 360, Property, Plant and Equipment, When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the six months ended June 30, 2022 and 2021, the Company determined no impairment was required.
New Accounting Pronouncements	The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Significant Accounting Policies
Schedule of Future Amortization Expense	Year Amount 2022 (remaining) $ 2,025 2023 4,050 2024 4,050 2025 4,050 2026 4,050 Thereafter 20,250 $ 38,475

Issuances of Securities (Tables

Issuances of Securities (Tables)	6 Months Ended
	Jun. 30, 2022
Issuances of Securities
Schedule of Restricted stock units	Weighted Average Grant Number of Date Fair Units Value Total awards outstanding at December 31, 2021 28,190,000 $ 0.96 Units granted 14,225,000 $ 0.43 Units Exercised/Released - $ - Units Cancelled/Forfeited (11,500,000 ) $ 1.18 Total awards outstanding at June 30, 2022 30,915,000 $ 0.63

Significant Accounting Polici_4

Significant Accounting Policies (Details)	Jun. 30, 2022 USD ($)
Significant Accounting Policies
2022 (remaining)	$ 2,025
2023	4,050
2024	4,050
2025	4,050
2026	4,050
Thereafter	20,250
Future Amortization Expense	$ 38,475

Significant Accounting Polici_5

Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Accumulated amortization	$ 2,025		$ 0
Bad debt expense	0	$ 0
Amortization expense	$ 2,025	$ 0
Description of patent	straight-line basis over the estimated useful life of 10 years
Series A Convertible Preferred Stock [Member]
Potential antidilutive shares	30,915,000	28,325,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 06, 2021	Nov. 30, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Interest expense - related party			$ 11,535	$ 0	$ 20,343	$ 389,804
Total fair value					204,000
Accrued interest			22,651		22,651			$ 2,308
Stock based compensation					$ 310,200	$ 26,512,173
Restricted stock units, vesting		13,225,000
Maturity Date					Dec. 31, 2021
Shares issued for services, shares					200,000
Brian Thom [Member]
Restricted stock units, vesting		11,500,000
Loss on settlement of debt							$ 27,000
Fair market value			$ 72,000
Amount owed					$ 490,000
Interest Rate					10%
Maturity Date					Dec. 31, 2022
Accrued compensation							45,000	899
Loan amount					$ 315,000
Shares issued for services, shares			150,000		150,000
Reimbursable expenses					$ 899
Convertible loans payable - related parties								175,000
Mr. Beplate [Member]
Shares issued for services, shares						2,000,000
Common stock share issued	2,000,000
Converted loans payable and accrued liabilities							100,000
Shares issued	21,970,000
Officers And Directors [Member]
Shares issued for services, shares						32,255,000
Shares issued					1,000,000
Louis Schiliro [Member]
Loss on settlement of debt							27,000
Fair market value			$ 72,000
Amount owed					$ 108,275
Interest Rate					10%
Maturity Date					Dec. 31, 2022
Accrued compensation							45,000	0
Loan amount					$ 64,275
Shares issued for services, shares			150,000		150,000
Restricted stock units granted					2,000,000
Remaining balance								44,000
Kristofer Heaton [Member]
Loss on settlement of debt			$ 22,500		$ 22,500
Fair market value					60,000
Amount owed					$ 4,000
Interest Rate					10%
Maturity Date					Dec. 31, 2022
Accrued compensation							$ 37,500	$ 0
Loan amount					$ 4,000
Additional RSU's issued							100,000
Shares issued for services, shares			125,000		125,000
Douglas Beplate [Member]
Restricted stock units granted					6,760,000
RSU granted to officers, directors and consultants					2,000,000

Promissory Note Payable (Detail

Promissory Note Payable (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Nov. 30, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Accrued		$ 120,000		$ 120,000		$ 120,000
Maturity Date				Dec. 31, 2021
Promissory note payable		63,739		$ 63,739		$ 0
Repayments on loan payable				36,261	$ 0
Interest expense		$ 205	$ 4,413	285	$ 225,639
Restricted stock units, vesting	13,225,000
Legal Counsel [Member]
Monthly payments				$ 9,136
Accrues interest		1%		1%
Promissory note		$ 100,000		$ 100,000
Promissory note payable		63,739		63,739
Repayments on loan payable				36,261
Interest expense				285
Accrued interest		$ 0		$ 0
Restricted stock units, vesting				200,000
Payment for settlement of debt				$ 20,000

Issuances of Securities (Detail

Issuances of Securities (Details)	6 Months Ended
	Jun. 30, 2022 shares
Issuances of Securities (Details)
Number of units total awards outstanding, beginning	28,190,000
Number of units granted	14,225,000
Number of units cancelled/forfeited	(11,500,000)
Number of units total awards outstanding, ending	30,915,000
Weighted average total awards outstanding, beginning	0.96
Weighted average units granted	0.43
Weighted average units exercised/released	0
Weighted average units cancelled/forfeited	1.18
Weighted average total awards outstanding, ending	0.63

Issuances of Securities (Deta_2

Issuances of Securities (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Jan. 06, 2021
Unrecognized compensation cost	$ 19,563,950
Common stock shares cancellations		117,647
Common stock shares cancellations payable and accrued interest		676,555
Additional paid-in capital		$ 117
common stock with a fair value issued	$ 76,500
common stock with a fair value issued shares	$ 0.001		$ 0.001
Stock based compensation expense	$ 23,947,300
Common stock, shares issued for service rendered, shares	200,000
Common stock shares cancellations payable and accrued interest	229,877,509		228,667,229
Board of Directors [Member]
Stock-based compensation expense	$ 23,947,300
Restricted stock units granted	21,970,000
Robert Denser [Member]
Restricted stock units granted	13,225,000			11,500,000
January 1, 2021 [Member]
Restricted stock unit, vested	9,960,000
Stock-based compensation expense		$ 43,121
Mr. Beplate [Member]
Common stock, shares issued for service rendered, shares		2,000,000
Common stock, shares issued for service rendered, amount		$ 2,180,000
Officers And Directors [Member]
Common stock, shares issued for service rendered, shares		32,255,000
Common stock, shares issued for service rendered, amount		$ 24,221,170
Officer And Former Officer [Member]
Additional paid-in capital	$ 250
Common stock, shares issued for service rendered, shares	20,000
Common stock with a fair value	$ 204,000
Common stock shares cancellations payable and accrued interest	250,000
Common stock, fair value	$ 10,200
Affiliated Investor [Member] | Private Placement [Member]
Common stock, shares issued for service rendered, shares		125,000
Common stock, shares issued for service rendered, amount		$ 100,000
Non Affiliated Investor [Member] | Private Placement [Member]
Common stock, shares issued for service rendered, shares	206,252
Cash proceeds	$ 77,292
Loss on settlement of debt	36,875
Accrued liabilities	63,126
Fair value	$ 96,000
Shares issued for consultants services	$ 425,000
Accrued liabilities related party	$ 127,500
Common stock, shares issued for service rendered, amount		100,000
Common stock sold	184,028
Consultants [Member]
Cash proceeds		$ 111,000
Related Party [Member]
Shares issued for settel accrued liability, shares		152,835
Cash proceeds		$ 20,000
Common stock shares issued during the period		25,000
Shares issued for settel accrued liability, amount		$ 133,523
Debt instrument, conversion of shares		1,085,135
Common stock issued for conversion of convertible notes payable and accrued interest - related party, shares		1,353,111
Conversion of Stock, Shares Issued		590,468

Accrued Litigation Settlement (

Accrued Litigation Settlement (Details Narrative) - USD ($)	1 Months Ended
	Jun. 15, 2022	Jun. 30, 2022
Civil penalty amount	$ 450,000
Initial schedule payment civil penalty		$ 50,000
Accrued litigation balance		$ 400,000
Installment One [Member]
Civil penalty amount	50,000
Installment Two [Member]
Civil penalty amount	100,000
Installment Three [Member]
Civil penalty amount	150,000
Installment Four [Member]
Civil penalty amount	$ 150,000

Litigation (Details Narrative)

Litigation (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Accrued	$ 120,000	$ 120,000
Shares declare to be free trading	3,050,000
Litigation settlement, shares issuable under agreement, fair value	$ 120,000
Lead Dog Capital LP [Member]
Loss contingency damages sought, description	in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third-party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading
Former Chief Executive Officer and Chief Medical Advisor [Member]
Compensatory damages	$ 2,795,000
Loss contingency damages sought, punitive damages	$ 8,280,000

Other Income (Details Narrative

Other Income (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Other income	$ 0	$ 0	$ 0	$ 304,273
Maxim Group LLC [Member]
Other income			$ 304,273	$ 304,273

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Maturity date	Dec. 31, 2021
Board of Directors [Member]
RSU's granted | shares	16,000,000
Director [Member]
Convertible note issued to non-affiliate	$ 100,000
Convertible note bearing interest rate	10%
Maturity date	Dec. 31, 2023
Conversion price per share | $ / shares	$ 0.35
Original issue discount percenatge	7%
Net proceeds from convertible notes issued	$ 93,000
Non Affiliate Investor [Member]
Convertible note issued to non-affiliate	$ 200,000
Convertible note bearing interest rate	10%
Maturity date	Nov. 30, 2022
Conversion price per share | $ / shares	$ 0.40
Non Affiliate Investor One [Member]
Convertible note issued to non-affiliate	$ 100,000
Convertible note bearing interest rate	10%
Maturity date	Dec. 31, 2023
Conversion price per share | $ / shares	$ 0.35
Original issue discount percenatge	7%
Net proceeds from convertible notes issued	$ 93,000